EVOFEM BIOSCIENCES INC (EVFM) Stock Price & Overview
NASDAQ:EVFM • US30048L2034
Current stock price
The current stock price of EVFM is 0.4782 USD. Today EVFM is down by -23.37%. In the past month the price decreased by -58.42%. In the past year, price decreased by -95.52%.
EVFM Key Statistics
- Market Cap
- 20.18M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -15.30
- Dividend Yield
- N/A
EVFM Stock Performance
EVFM Stock Chart
EVFM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to EVFM. When comparing the yearly performance of all stocks, EVFM is a bad performer in the overall market: 98.86% of all stocks are doing better.
EVFM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EVFM. EVFM may be in some trouble as it scores bad on both profitability and health.
EVFM Earnings
On August 4, 2022 EVFM reported an EPS of -0.03 and a revenue of 7.10M.
EVFM Forecast & Estimates
11 analysts have analysed EVFM and the average price target is 11.27 USD. This implies a price increase of 2256.96% is expected in the next year compared to the current price of 0.4782.
For the next year, analysts expect an EPS growth of 57.85% and a revenue growth 295.01% for EVFM
EVFM Groups
Sector & Classification
EVFM Financial Highlights
Over the last trailing twelve months EVFM reported a non-GAAP Earnings per Share(EPS) of -15.3. The EPS decreased by -553.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -1676.29% | ||
| ROA | -552.28% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
EVFM Ownership
EVFM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.52 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.69 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.35 | 298.838B | ||
| PFE | PFIZER INC | 9.32 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.37 | 121.374B | ||
| ZTS | ZOETIS INC | 16.71 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.16 | 28.018B | ||
| VTRS | VIATRIS INC | 5.35 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.69 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 49.44 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EVFM
Company Profile
Evofem Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
Company Info
IPO: 2014-11-20
EVOFEM BIOSCIENCES INC
12400 High Bluff Dr Ste 600
San Diego CALIFORNIA 92130 US
CEO: Saundra Pelletier
Employees: 119
Phone: 18585501900.0
EVOFEM BIOSCIENCES INC / EVFM FAQ
Can you describe the business of EVOFEM BIOSCIENCES INC?
Evofem Biosciences Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in San Diego, California and currently employs 119 full-time employees. The company went IPO on 2014-11-20. Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The company is engaged in developing and commercializing products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Its product, Phexxi vaginal gel, is a hormone-free, woman-controlled, on-demand prescription contraceptive gel for women. Its lead clinical program is evaluating Phexxi (using the investigational name EVO100) for the prevention of chlamydia and gonorrhea in women. EVO200 vaginal gel (EVO200), its investigational candidate for the reduction of recurrent bacterial vaginosis (BV), uses the same vaginal potential of hydrogen (pH) modulator platform as Phexxi. The company also focuses on developing Multipurpose Prevention Technology (MPT) vaginal gel for indications, including the prevention of human immunodeficiency virus (HIV) in women through Orion Biotechnology Canada Ltd.
What is the current price of EVFM stock?
The current stock price of EVFM is 0.4782 USD. The price decreased by -23.37% in the last trading session.
What is the dividend status of EVOFEM BIOSCIENCES INC?
EVFM does not pay a dividend.
What is the ChartMill technical and fundamental rating of EVFM stock?
EVFM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is EVOFEM BIOSCIENCES INC (EVFM) stock traded?
EVFM stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of EVOFEM BIOSCIENCES INC (EVFM)?
EVOFEM BIOSCIENCES INC (EVFM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-15.3).
Is EVOFEM BIOSCIENCES INC (EVFM) expected to grow?
The Revenue of EVOFEM BIOSCIENCES INC (EVFM) is expected to grow by 295.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.